3B Pharmaceuticals Technographics
Discover the latest software purchases and digital transformation initiatives being undertaken by 3B Pharmaceuticals and its business and technology executives. Each quarter our research team identifies on-prem and cloud applications that are being used by the 150 3B Pharmaceuticals employees from the public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources.
During our research, we have identified that 3B Pharmaceuticals has purchased the following applications: IDBS ActivityBase for Analytics and BI in 2020 and the related IT decision-makers and key stakeholders.
Our database provides customer insight and contextual information on which enterprise applications and software systems 3B Pharmaceuticals is running and its propensity to invest more and deepen its relationship with IDBS or identify new suppliers as part of their overall Digital and IT transformation projects to stay competitive, fend off threats from disruptive forces, or comply with internal mandates to improve overall enterprise efficiency.
We have been analyzing 3B Pharmaceuticals revenues, which have grown to $70.0 million in 2024, plus its IT budget and roadmap, cloud software purchases, aggregating massive amounts of data points that form the basis of our forecast assumptions for 3B Pharmaceuticals intention to invest in emerging technologies such as AI, Machine Learning, IoT, Blockchain, Autonomous Database or in cloud-based ERP, HCM, CRM, EPM, Procurement or Treasury applications.
Analytics and BI
Vendor |
Previous System |
Application |
Category |
Market |
VAR/SI |
When |
Live |
Insight |
|---|---|---|---|---|---|---|---|---|
| IDBS | Legacy | IDBS ActivityBase | Analytics and BI | Analytics and BI | n/a | 2020 | 2020 |
In 2020, 3B Pharmaceuticals expanded its use of IDBS ActivityBase, deploying the IDBS ActivityBase platform as its central research data repository to address Analytics and BI needs across the organization. The company moved from a project-limited footprint to a company-wide roll-out that aimed to broaden access to assay data and analysis beyond a few experts to all scientists.
The implementation combined IDBS ActivityBase as the canonical data store with SARview and SARgen as the query and SAR analysis layer, enabling cross-project compound-centric queries. New import templates were created to ingest assay data from additional departments including analytics and radiochemistry, and data validation procedures were configured to ensure that only the most up-to-date records are surfaced to project leaders.
Operational coverage extended to all scientists and research projects, unifying assay results across departments so queries could run across the full set of data for a given compound. IDBS and its partners provided user training and support for template creation and user onboarding, embedding ActivityBase into routine research workflows and enabling broader self-service analysis by scientists.
Governance was tightened through standardized templates and implemented data validation workflows that fed decision-making by project leaders. Outcomes explicitly reported by 3B Pharmaceuticals include improved research productivity, stronger data integrity, and higher quality of decision making as a result of the expanded ActivityBase roll-out.
|
| First Name | Last Name | Title | Function | Department | Phone | |
|---|---|---|---|---|---|---|
| No data found | ||||||
| Date | Company | Status | Vendor | Product | Category | Market |
|---|---|---|---|---|---|---|
| No data found | ||||||